Related Experiment Video
Updated: Jun 24, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Chronic lymphocytic leukaemia: current first-line therapy.
1Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Victoria, Australia.
Internal Medicine Journal
|March 18, 2009
Summary
First-line therapy for chronic lymphocytic leukemia (CLL) is evolving. Fludarabine-based treatments and chemoimmunotherapy, including rituximab, show superior outcomes compared to older alkylating agents for CLL patients.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Chronic lymphocytic leukemia (CLL) treatment is undergoing significant changes.
- Traditional alkylating agent therapy is being compared against newer treatment regimens.
Purpose of the Study:
- To review the evolving landscape of first-line therapy for chronic lymphocytic leukemia.
- To highlight the efficacy of fludarabine-based regimens and monoclonal antibodies.
Main Methods:
- Review of recent large clinical trials in CLL therapy.
- Analysis of outcomes comparing fludarabine-based therapy, alkylating agents, and monoclonal antibodies like rituximab.
Main Results:
- Fludarabine-based therapy demonstrates superior outcomes compared to alkylating agents in CLL.
- Monoclonal antibodies, particularly rituximab, are crucial for targeted CLL treatment.
- Chemoimmunotherapy is emerging as a preferred future treatment for many CLL patients.
Conclusions:
- Chemoimmunotherapy represents a significant advancement in first-line CLL treatment.
- Optimal treatment strategies for specific patient subgroups (elderly, autoimmune hemolytic anemia, P53 mutations) require further investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...